Ampac Fine Chemicals revenues declined 23% in the year ended 30 September 2009. Ampac said the decline in revenues could be attributed to declines in core product revenues from anti-viral products of 30%, central nervous system products of 14%, and oncology products of 13%.
Seeking Alpha
Sunday 27 December 2009
Ampac Fine Chemicals revenues decline
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment